World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder.
about
Sertraline versus other antidepressive agents for depressionSertraline versus other antidepressive agents for depressionAgomelatine: The evidence for its place in the treatment of depressionMAO-inhibitors in Parkinson's DiseaseIs remission of depressive symptoms in primary care a realistic goal? A meta-analysisOptimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical PracticePharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug responseConsiderations on the ICD-11 classification of psychotic depressionThe noradrenergic action in antidepressant treatments: pharmacological and clinical aspectsThe effects of centralised and specialised intervention in the early course of severe unipolar depressive disorder: a randomised clinical trialThe GABAergic deficit hypothesis of major depressive disorder.gamma-Aminobutyric acid-type A receptor deficits cause hypothalamic-pituitary-adrenal axis hyperactivity and antidepressant drug sensitivity reminiscent of melancholic forms of depression.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreLithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Substance Use and Related Disorders, Part 1: Alcoholism.Binding and orientation of tricyclic antidepressants within the central substrate site of the human serotonin transporter.Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.Meta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorderAn evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report.Convergent evidence from mouse and human studies suggests the involvement of zinc finger protein 326 gene in antidepressant treatment response.Can we really prevent suicide?Current place of monoamine oxidase inhibitors in the treatment of depression.Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.Efficacy of an adjunctive brief psychodynamic psychotherapy to usual inpatient treatment of depression: rationale and design of a randomized controlled trial.A Meta-Analysis Comparing Open-Label versus Placebo-Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and PromisesThe World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders.Effectiveness of lithium in subjects with treatment-resistant depression and suicide risk: a protocol for a randomised, independent, pragmatic, multicentre, parallel-group, superiority clinical trial.Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression.The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants.Effects of different antidepressant treatments on the core of depression.Antidepressant prescribing patterns in Korea: results from the clinical research center for depression studyWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015.Medication options in the treatment of treatment-resistant depression.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.Monoamine transporters: vulnerable and vital doorkeepers.Effectiveness and outcome predictors of long-term lithium prophylaxis in unipolar major depressive disorder.The impact of lithium long-term medication on suicidal behavior and mortality of bipolar patients.Duloxetine: a new selective and dual-acting antidepressant.
P2860
Q24235928-6669FCFA-F0E2-44E0-98A8-3337D415C8D0Q24241023-4DF10E2F-DD8D-4F71-872E-EB8F2D70F886Q24617019-3E5FF0CE-9D2A-49BA-BD5D-C535CC731933Q24629770-5E27479F-E2F8-4701-A67D-79ACBADF7CB3Q24794437-70AFC783-C070-4F0C-B1AB-642D435D23D7Q26797416-97DD0F89-A36F-473D-9C26-5804C4DCE6DBQ28252209-8CC73E0D-58B7-4526-9843-30C0AAD0BA40Q28261431-472C5ED4-FE8F-4EA5-BBBB-8DE2E0E6425EQ28300843-DFCFFAE7-9F6E-46FA-B51F-50EF6D46622AQ28731231-90DD3C5C-AE31-411E-8BE7-38B50F528648Q30464954-4152C603-43D6-4BC7-B8AB-6C8FCCD06110Q30496339-C1FB85A6-3406-4454-93D1-382C3CD61A78Q31121202-784D9550-9CB9-4C3B-9E30-FF67A1A271ABQ31156853-00B71F2F-EB4E-430F-99EF-AD4BCA0B184EQ33319816-152E32E1-E874-4171-BB18-153DC639EAC7Q33707171-F8D67303-EA9C-4ECA-9C2F-3C15EB2F6AF1Q33799660-85A1610B-C798-4BF5-BFE7-020D7214EFE0Q34010693-B8A958E4-8EB8-442A-B0C2-234C449AA0FEQ34090610-5B056EA4-822A-42E6-856A-EAA3C8E8F8A5Q34292369-B451C4D6-0E49-411C-9F79-DAEEE33D209AQ34300877-C54E7E06-8495-4345-9A89-CD33AE508E15Q34363276-E896E611-ED7B-4BF4-B59D-8CFF8D82BE7DQ34393030-6395D16B-5C12-424C-9877-EACA52ED295FQ34461546-1F35D667-C4B0-42C8-BEF2-76368A9AA0B9Q34476432-F940C650-9C43-4D07-9E61-EBD91C27CB4BQ34531273-C1E3D154-A900-4CF4-94C2-03AECA0B8367Q34578945-6E9EC8FF-A354-4478-86CE-F8EADC4D07F2Q34584223-9A48EE4A-3A83-454D-A853-57C3DDD659D5Q34939218-483CAB89-67E3-4BAC-B82D-5EDB63463CD0Q35101679-53FC01C2-CE2D-40AD-B1E5-DB130E3EEB02Q35236618-ED6937FC-F512-471B-9606-2373801D203FQ35237015-116859DB-48E1-4BE6-B48F-7373AA9039CEQ35238344-32E41F5E-6D64-4078-84C6-F3411BD0BED8Q35560309-A5964D61-0318-4D47-B200-68AC0BF6DC18Q35707515-6133CEF7-FDCD-4B62-B5ED-5DCF4BB77594Q35862776-D4D86D91-6BE2-4148-AEA8-8C28CBF9BD2DQ35877150-EA3E0C65-E97A-400A-B6A2-FCF9733EFB5FQ35924815-B23E3F31-FE50-42BC-A37A-DD83EEC591AEQ36195205-2730F97B-341B-41D8-B4F6-4F17D154DCA1Q36407366-E2A84CC0-B98B-46B7-AB53-722E8A2E0013
P2860
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
World Federation of Societies ...... of major depressive disorder.
@ast
World Federation of Societies ...... of major depressive disorder.
@en
type
label
World Federation of Societies ...... of major depressive disorder.
@ast
World Federation of Societies ...... of major depressive disorder.
@en
prefLabel
World Federation of Societies ...... of major depressive disorder.
@ast
World Federation of Societies ...... of major depressive disorder.
@en
P2093
P2860
P1476
World Federation of Societies ...... of major depressive disorder.
@en
P2093
Jules Angst
Marcio Versiani
Michael Bauer
World Federation of Societies ...... Unipolar Depressive Disorders
P2860
P356
10.3109/15622970209150599
P577
2002-01-01T00:00:00Z